Menna P - Search Results

1

Safety and tolerability of a novel oral nutritional supplement in healthy volunteers.

Bonelli A, Menna P, Minotti G, Angeletti S, Comandini A, Picollo R, Quarchioni E, Russo V, Salvatori E, Ferravante F, Emerenziani S, Cicala M, Muscaritoli M. Bonelli A, et al. Among authors: menna p. Clin Nutr. 2021 Mar;40(3):946-955. doi: 10.1016/j.clnu.2020.06.022. Epub 2020 Jul 1. Clin Nutr. 2021. PMID: 32675020 Free article. Clinical Trial.

2

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, Minotti G. Sacco G, et al. Among authors: menna p. Br J Pharmacol. 2003 Jun;139(3):641-51. doi: 10.1038/sj.bjp.0705270. Br J Pharmacol. 2003. PMID: 12788824 Free PMC article.

3

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P, Minotti G. Cartoni A, et al. Among authors: menna p. J Biol Chem. 2004 Feb 13;279(7):5088-99. doi: 10.1074/jbc.M306568200. Epub 2003 Nov 21. J Biol Chem. 2004. PMID: 14634026 Free article.

4

In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.

Menna P, Minotti G, Salvatorelli E. Menna P, et al. Cell Biol Toxicol. 2007 Jan;23(1):49-62. doi: 10.1007/s10565-006-0143-8. Epub 2006 Oct 9. Cell Biol Toxicol. 2007. PMID: 17031515 Review.

5

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Gianni L, Minotti G. Salvatorelli E, et al. Among authors: menna p. J Pharmacol Exp Ther. 2007 Feb;320(2):790-800. doi: 10.1124/jpet.106.116160. Epub 2006 Nov 29. J Pharmacol Exp Ther. 2007. PMID: 17135345

6

Doxorubicin degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G. Menna P, et al. J Pharmacol Exp Ther. 2007 Jul;322(1):408-19. doi: 10.1124/jpet.107.122820. Epub 2007 Apr 27. J Pharmacol Exp Ther. 2007. PMID: 17468298

7

An introduction to the metabolic determinants of anthracycline cardiotoxicity.

Menna P, Recalcati S, Cairo G, Minotti G. Menna P, et al. Cardiovasc Toxicol. 2007;7(2):80-5. doi: 10.1007/s12012-007-0011-7. Cardiovasc Toxicol. 2007. PMID: 17652809 Review.

8

Cardiotoxicity of antitumor drugs.

Menna P, Salvatorelli E, Minotti G. Menna P, et al. Chem Res Toxicol. 2008 May;21(5):978-89. doi: 10.1021/tx800002r. Epub 2008 Apr 1. Chem Res Toxicol. 2008. PMID: 18376852

9

Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.

Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G. Salvatorelli E, et al. Among authors: menna p. J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14. J Pharmacol Exp Ther. 2009. PMID: 19144686

10

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G. Menna P, et al. Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p. Chem Res Toxicol. 2009. PMID: 19397277

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page